Status:

RECRUITING

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Neoplasm Malignant

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many ...

Eligibility Criteria

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has locally advanced unresectable or metastatic solid tumor malignancy other than colorectal cancer and has progressed on, or following, standard of care systemic treatment
  • Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system metastases and/or carcinomatous meningitis and/or primary brain tumors
  • Has active infection, other than those permitted per protocol, requiring systemic therapy
  • Has not adequately recovered from major surgery or has ongoing surgical complications

Key Trial Info

Start Date :

December 4 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 9 2032

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT07209111

Start Date

December 4 2025

End Date

April 9 2032

Last Update

April 13 2026

Active Locations (44)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (44 locations)

1

Greater Baltimore Medical Center ( Site 1104)

Baltimore, Maryland, United States, 21204

2

START Midwest ( Site 1103)

Grand Rapids, Michigan, United States, 49546

3

Comprehensive Cancer Centers of Nevada ( Site 1109)

Las Vegas, Nevada, United States, 89169

4

Rutgers Cancer Institute of New Jersey ( Site 1100)

New Brunswick, New Jersey, United States, 08903